Tag: Evidence-based Practice

Joint Commission conducting both virtual and onsite surveys in 2021

The Joint Commission stopped doing most onsite surveys and reviews from March 16 to May 31, 2020, in response to the COVID-19 pandemic. During that time, they developed processes for conducting offsite or virtual events, and as of mid-December, more than 1,200 offsite surveys and reviews had been conducted across…

Read More

By: Judith M. Mathias, MA, RN
February 17, 2021
Share

Study finds lasting protection in patients who have recovered from COVID-19

Editor's Note This study led by researchers at the Massachusetts General Hospital and Harvard Medical School, Boston, finds that patients who survive serious COVID-19 infections have a long-lasting immune response against the virus. The study includes a cohort of case patients with known COVID-19 infection (343) and controls (1,548). Blood…

Read More

By: Judy Mathias
October 15, 2020
Share

Study: Remdesivir vs placebo for COVID-19 treatment

Editor's Note In this double-blind, randomized, placebo-controlled study of IV remdesivir in adults hospitalized with COVID-19 and lower respiratory tract infection, remdesivir was found to be superior to placebo in shortening the time to recovery. A total of 1,062 patients were randomized to either remdesivir (541) or placebo (521). Remdesivir…

Read More

By: Judy Mathias
October 13, 2020
Share

Joint Commission seeks feedback on proposed requirements for spine surgery certification

Editor's Note The Joint Commission on September 23 announced that it is seeking feedback on proposed requirements for its Advanced Certification in Spine Surgery. In collaboration with the American Academy of Orthopaedic Surgeons, the Joint Commission developed the proposed spine surgery related requirements to include: program structure delivery of care…

Read More

By: Judy Mathias
September 24, 2020
Share

Researchers discover predictors of COVID-19 severity, survival

Editor's Note In this study from Mount Sinai Hospital and School of Medicine, New York City, researchers identify two markers of inflammation that reliably predict the severity of COVID-19 and likelihood of survival. A total of 1,484 patients were followed up to 41 days after admission, and the findings were…

Read More

By: Judy Mathias
August 27, 2020
Share

Culture, communication, and clinical skills essential for ERAS success

Strategies that can achieve the aims of excellence in clinical care, fewer complications, and reduced costs are sorely needed, and the comprehensive implementation of an Enhanced Recovery After Surgery (ERAS) program can help achieve these aims in the surgical population. ERAS pathways have been found to reduce morbidity, hospital stay,…

Read More

By: OR Manager
July 22, 2020
Share

Study: Hydroxychloroquine lowers COVID-19 death rate

Editor's Note In this study, researchers from Henry Ford Health System in Michigan found that hydroxychloroquine alone decreased the mortality hazard ratio of COVID-19 by 66%, and hydroxychloroquine with azithromycin decreased the ratio by 71%, compared to neither treatment. The vast majority of the 2,541 COVID-19 patients included in the…

Read More

By: Judy Mathias
July 6, 2020
Share

ACP: Use of N95, surgical, and cotton masks to prevent COVID-19

Editor's Note: The American College of Physicians (ACP) on June 18 issued new practice points on the effectiveness of N95 respirators, surgical masks, and cloth masks for the prevention of COVID-19 in addition to standard precautions in healthcare and community settings. The ACP Practice Points, which were funded by the…

Read More

By: Judy Mathias
June 22, 2020
Share

Lancet, NEJM retract COVID-19 treatment studies

Editor's Note The Lancet and New England Journal of Medicine (NEJM) have both retracted COVID-19 treatment studies because of concerns about the validity of the data and how the research was conducted by Chicago-based Surgisphere Corp, the June 4 Medscape Medical News reports. Authors of the Lancet study, which was…

Read More

By: Judy Mathias
June 8, 2020
Share

NIH begins clinical trial of hydroxychloroquine, azithromycin for COVID-19 treatment

Editor's Note The National Institutes of Health (NIH) on May 14 announced that it is enrolling adults with mild to moderate COVID-19 in a study of treatment with hydroxychloroquine and azithromycin. The Phase 2b trial is enrolling around 2,000 adults across the US. Participants must have confirmed infection with SARS-CoV-2…

Read More

By: Judy Mathias
May 19, 2020
Share

Join our community

Learn More
Video Spotlight
Live chat by BoldChat